These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29378276)

  • 21. Nanostructured materials for ocular delivery: nanodesign for enhanced bioadhesion, transepithelial permeability and sustained delivery.
    Kim J; Schlesinger EB; Desai TA
    Ther Deliv; 2015; 6(12):1365-76. PubMed ID: 26652282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ocular drug delivery-eye on innovation.
    Rupenthal ID; O'Rourke M
    Drug Deliv Transl Res; 2016 Dec; 6(6):631-633. PubMed ID: 27766597
    [No Abstract]   [Full Text] [Related]  

  • 23. Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye - Part I - Barriers and determining factors in ocular delivery.
    Sánchez-López E; Espina M; Doktorovova S; Souto EB; García ML
    Eur J Pharm Biopharm; 2017 Jan; 110():70-75. PubMed ID: 27789358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel strategies for anterior segment ocular drug delivery.
    Cholkar K; Patel SP; Vadlapudi AD; Mitra AK
    J Ocul Pharmacol Ther; 2013 Mar; 29(2):106-23. PubMed ID: 23215539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations.
    Short BG
    Toxicol Pathol; 2008 Jan; 36(1):49-62. PubMed ID: 18337221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ISOPT
    Kompella UB; Domb A; Urtti A; Jayagopal A; Wilson CG; Tang-Liu D
    J Ocul Pharmacol Ther; 2019 Oct; 35(8):457-465. PubMed ID: 31259643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topical ocular drug delivery: recent developments and future challenges.
    Lee VH; Robinson JR
    J Ocul Pharmacol; 1986; 2(1):67-108. PubMed ID: 3332284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dendrimer nanoparticles for ocular drug delivery.
    Kambhampati SP; Kannan RM
    J Ocul Pharmacol Ther; 2013 Mar; 29(2):151-65. PubMed ID: 23410062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dendrimers as a promising tool in ocular therapeutics: Latest advances and perspectives.
    Rodríguez Villanueva J; Navarro MG; Rodríguez Villanueva L
    Int J Pharm; 2016 Sep; 511(1):359-366. PubMed ID: 27436708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chitosan-based nanostructures: a delivery platform for ocular therapeutics.
    de la Fuente M; Raviña M; Paolicelli P; Sanchez A; Seijo B; Alonso MJ
    Adv Drug Deliv Rev; 2010 Jan; 62(1):100-17. PubMed ID: 19958805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: Pharmacokinetic studies on rabbits.
    Chetoni P; Burgalassi S; Monti D; Tampucci S; Tullio V; Cuffini AM; Muntoni E; Spagnolo R; Zara GP; Cavalli R
    Eur J Pharm Biopharm; 2016 Dec; 109():214-223. PubMed ID: 27789355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery.
    Dutescu RM; Panfil C; Merkel OM; Schrage N
    Eur J Pharm Biopharm; 2014 Sep; 88(1):123-8. PubMed ID: 24844949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chitosan Nanoparticles as a Mucoadhesive Drug Delivery System for Ocular Administration.
    Silva MM; Calado R; Marto J; Bettencourt A; Almeida AJ; Gonçalves LMD
    Mar Drugs; 2017 Dec; 15(12):. PubMed ID: 29194378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparative study on the efficiency of chitosan-N-acetylcysteine, chitosan oligosaccharides or carboxymethyl chitosan surface modified nanostructured lipid carrier for ophthalmic delivery of curcumin.
    Li J; Liu D; Tan G; Zhao Z; Yang X; Pan W
    Carbohydr Polym; 2016 Aug; 146():435-44. PubMed ID: 27112894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ophthalmic drug delivery considerations at the cellular level: drug-metabolising enzymes and transporters.
    Attar M; Shen J; Ling KH; Tang-Liu D
    Expert Opin Drug Deliv; 2005 Sep; 2(5):891-908. PubMed ID: 16296785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug delivery to the eye: what benefits do nanocarriers offer?
    Joseph RR; Venkatraman SS
    Nanomedicine (Lond); 2017 Mar; 12(6):683-702. PubMed ID: 28186436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fabrication and evaluation of lipid nanoparticulates for ocular delivery of a COX-2 inhibitor.
    Sharma AK; Sahoo PK; Majumdar DK; Sharma N; Sharma RK; Kumar A
    Drug Deliv; 2016 Nov; 23(9):3364-3373. PubMed ID: 27128623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trans-scleral delivery of macromolecules.
    Pescina S; Santi P; Ferrari G; Nicoli S
    Ther Deliv; 2011 Oct; 2(10):1331-49. PubMed ID: 22826887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanostructured lipid carriers as novel ophthalmic delivery system for mangiferin: improving in vivo ocular bioavailability.
    Liu R; Liu Z; Zhang C; Zhang B
    J Pharm Sci; 2012 Oct; 101(10):3833-44. PubMed ID: 22767401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmaceutical microscale and nanoscale approaches for efficient treatment of ocular diseases.
    Bravo-Osuna I; Andrés-Guerrero V; Pastoriza Abal P; Molina-Martínez IT; Herrero-Vanrell R
    Drug Deliv Transl Res; 2016 Dec; 6(6):686-707. PubMed ID: 27766598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.